everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...3637383940414243444546...132133»
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Biomarker, Clinical, Journal:  Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer. (Pubmed Central) -  Dec 16, 2021   
    In contrast, PIK3CA mutations were significantly associated with longer TTP in patients receiving EverX treatment (median TTP of EverX: 15.9 months vs. 5.2 months, p = 0.01) and remained a significant factor in multivariable analysis for TTP of EverX in this subgroup (hazard ratio = 0.2, 95% CI = 0.1- 0.8, p = 0.03). ESR1 and PIK3CA mutations in cfDNA were associated with clinical efficacies of ET in HR+ MBC patients.
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Review, Journal:  Chemotherapy in NEN: still has a role? (Pubmed Central) -  Dec 16, 2021   
    Nevertheless, chemotherapy remains an essential component of the treatment armamentarium of patients with NENs, particularly of patients with P-NETs or those with bulky, symptomatic or rapidly progressive tumors (generally G3 or high-G2 NENs). In this manuscript we will comprehensively review available evidence related to the use of chemotherapy in lung and GEP NENs and will critically discuss its role in the treatment algorithm of this family of neoplasms.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Review, Journal:  The role and transformative potential of IL-19 in atherosclerosis. (Pubmed Central) -  Dec 16, 2021   
    Several other drugs have also been investigated in clinical trials as anti-inflammatory agents; the development of some of these agents has been terminated (canakinumab, darapladib, varespladib, losmapimod, atreleuton, setileuton, PF-04191834, veliflapon, and methotrexate), but others remain in development (ziltivekimab, tocilizumab, Somalix, IFM-2427, anakinra, mesenchymal stem cells (MSCs), colchicine, everolimus, allopurinol, and montelukast)...We propose that IL-19 is a promising biomarker and target for the diagnosis and treatment of atherosclerosis. This review considers the role and mechanism of action of IL-19 in atherosclerosis and discusses whether IL-19 is a potential therapeutic target for this condition.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal, IO biomarker:  Chemotherapy and targeted therapies for meningiomas: what is the evidence? (Pubmed Central) -  Dec 16, 2021   
    In recurrent high-grade meningioma, everolimus-octreotide combination, bevacizumab, sunitinib and peptide receptor radionuclide therapy exhibit a signal of activity that may justify their clinical use. Despite a lack of clear signal of activity to date, immunotherapy may offer new perspectives in the treatment of these refractory tumors.
  • ||||||||||  erastin - Whitehead Institute for Biomedical Research, Dana / Farber Cancer Institute, Columbia University, Prolexys, RSL3 / Stanford University, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma. (Pubmed Central) -  Dec 16, 2021   
    Moreover, the forced expression of GPX4 abrogated ferroptosis induced by the combined treatment of Everolimus and RSL3/Erastin. Taken together, these results demonstrated that Everolimus in combination with RSL3/Erastin is a promising therapeutic option for RCC treatment and it may also help to overcome the limitation in clinical applicability of Everolimus.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Retrospective data, Review, Journal:  Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. (Pubmed Central) -  Dec 16, 2021   
    While EVO can be a therapeutic option for therapy-resistant epilepsy in TSC, it can take a long time for seizure relief to manifest. The findings from this study suggest that a range of efficient therapies with different safety profiles is available for people with NETs.
  • ||||||||||  buparlisib (BKM120) / Novartis, Adlai Nortye, capivasertib (AZD5363) / Otsuka, AstraZeneca
    Journal:  Non-synaptic Cell-Autonomous Mechanisms Underlie Neuronal Hyperactivity in a Genetic Model of PIK3CA-Driven Intractable Epilepsy. (Pubmed Central) -  Dec 14, 2021   
    Finally, we report that acute inhibition of PI3K or AKT, but not MTOR activity, suppresses the intrinsic hyperactivity of the mutant neurons. These acute mechanisms are distinct from those causing neuronal hyperactivity in other AKT-MTOR epileptic models and define parameters to facilitate the development of new molecularly rational therapeutic interventions for intractable epilepsy.
  • ||||||||||  everolimus / Generic mfg.
    Clinical, Journal:  Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex. (Pubmed Central) -  Dec 14, 2021   
    Adverse events (AEs) were significantly less severe and less frequent over the course of maintenance therapy relative to standard therapy. Low-dose everolimus maintenance therapy represents an effective approach to achieving TSC-RAML control following a minimum of 6 months of full-dose induction therapy, and may be associated with decreases in everolimus-related AE frequency and severity.
  • ||||||||||  everolimus / Generic mfg.
    Clinical, Journal, Circulating Tumor Cells:  Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients. (Pubmed Central) -  Dec 13, 2021   
    These results illustrate the strength of a multiparametric CTC analysis to choose and validate targeted therapies to optimize cancer treatment in the future. Furthermore, from a scientific point of view, such studies promote the understanding of the biology of CTCs during different treatment regimens.
  • ||||||||||  everolimus / Generic mfg.
    Everolimus as a Precision Therapy for Drug-Resistant Seizures in the GATORopathies () -  Dec 12, 2021 - Abstract #AES2021AES_1310;    
    Diagnostic whole exome/genome sequencing should be considered in cases of refractory non-lesional epilepsy or refractory epilepsy due to focal cortical dysplasia. Preliminary data suggests that everolimus may be an effective targeted therapy for drug-resistant epilepsy caused by mutations in GATOR1 genes.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion:  CLEVER-ACS: Controlled Level EVERolimus in Acute Coronary Syndromes (clinicaltrials.gov) -  Dec 3, 2021   
    P1/2,  N=150, Completed, 
    It is expected that COMPOSE will inform optimal treatment options for patients with well-differentiated high grade 2 and grade 3 SSTR+ GEP-NETs, including for first-line therapy. Active, not recruiting --> Completed
  • ||||||||||  everolimus / Generic mfg.
    Clinical, Review, Journal:  Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. (Pubmed Central) -  Dec 2, 2021   
    Everolimus is an appropriate first-line choice for somatostatin receptor negative tumors and for any patients with progressive disease...Based on retrospective series, cytotoxic chemotherapy can be selected in patients with progressive tumors, primarily when cytoreduction is needed. Herein, we will discuss evidence supporting the role of adjuvant and systemic treatment therapies for those with bronchial carcinoid tumors by focusing on various studies.
  • ||||||||||  everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
    Clinical, Journal:  COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital. (Pubmed Central) -  Dec 2, 2021   
    A significant number of transplant recipients will be affected by COVID-19 (5.3%). Management of the infection will depend on the severity of the infection and must be based on a balance between reduction and adjustment of immunosuppression, strict control of the cardiologic situation, and treatment of the infection.
  • ||||||||||  Praluent (alirocumab) / Sanofi, Regeneron
    Clinical, Journal:  Treatment of Mixed Dyslipidemia With Alirocumab in a Kidney Transplant Recipient: A Case Report. (Pubmed Central) -  Dec 2, 2021   
    Our patient showed a mean reduction of 46.6% in LDL-C during an 18-month period after alirocumab initiation, which is comparable to the results of studies on patients with or without renal impairment. Furthermore, treatment with alirocumab proved to be well tolerated without adverse effects or interactions with the immunosuppression regimen.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Edema Associated With Everolimus de Novo. (Pubmed Central) -  Dec 2, 2021   
    The use of everolimus and standard doses of tacrolimus caused edema in 54% of patients, with no impact on renal function or survival compared with mycophenolic acid derivatives. The edema was mostly of low intensity and improved in most patients.
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    Trial completion, Adverse events, Combination therapy:  Comparing Everolimus and Sirolimus in Renal Transplant Recipients (clinicaltrials.gov) -  Nov 30, 2021   
    P=N/A,  N=60, Completed, 
    The edema was mostly of low intensity and improved in most patients. Active, not recruiting --> Completed
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Rapid Involution of Large Cardiac Rhabdomyomas With Everolimus Therapy. (Pubmed Central) -  Nov 29, 2021   
    We report a case of multiple large rhabdomyomas of the right and left ventricles, affecting the cardiac function, which was successfully treated with the chemotherapeutic and immunosuppressive medication everolimus, in a neonate with genetically confirmed tuberous sclerosis complex with multisystem manifestations. There was rapid involution of the tumors in response to everolimus therapy in this infant.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    GVHD TREATMENT () -  Nov 27, 2021 - Abstract #EHOC2021EHOC_170;    
    If no trial is available, ruxolitinib, mycophenolate mofetil, etanercept, extracorporeal photopheresis, anti-thymocyte globulin, alpha-1 antitrypsin, mesenchymal stromal cells, everolimus, or sirolimus can be used.Clinical manifestations of cGVHD may be restricted to a single organ or widespread...The addition of azathioprine,  mycophenolate mofetil, cyclosporine, thalidomide, or hydroxychloroquine to prednisone did not improve the response rate or other end-points in randomized trials...An immunosuppressive drug can be added to prednisone such as a calcineurin inhibitor or mycophenolate mofetil, but none shown to be effective. İbrutinib which is an inhibitor of Bruton's tyrosine kinase (BTK) has activity against cGVHD.
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal:  Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms. (Pubmed Central) -  Nov 25, 2021   
    Treatment options for non-pancreatic NETs are also expanding and while SSAs are the typical first-line option, everolimus and PRRT both remain approved therapies for future lines, and VEGF TKIs are showing promising results in research settings. Sequencing these agents and best time to incorporate peptide receptor radio therapy into the management algorithm remains an unmet need.
  • ||||||||||  Rydapt (midostaurin) / Novartis, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    New Anti-Cancer Drug Compounds to Treat Mutated Waldenstrom Myd88 L265P () -  Nov 24, 2021 - Abstract #ASH2021ASH_6769;    
    In this study, MWCL-1 cells (adult WM), expressing the Myd88 L265P mutation, were used to test different drugs to monitor their effect in cell proliferation and apoptosis activities, in comparison to midostaurin (an inhibitor of FLT3), for 24 hours treatment...The use of compound A at high concentration to reduce the number of MWCL-1 reflect the difficulties to treat WM patient with the existing approved drugs. Further studies will be necessary to understand more the molecular mechanism affected by the compound A and/or B in the TLR-IRAK4 pathway, and to study their effect in vivo .
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Journal:  Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? (Pubmed Central) -  Nov 24, 2021   
    Further studies will be necessary to understand more the molecular mechanism affected by the compound A and/or B in the TLR-IRAK4 pathway, and to study their effect in vivo . Treatment with further TKIs or mTOR inhibitors for mRCC patients primarily refractory to first-line sunitinib in the observed time period achieved very minimal benefit, suggesting avoiding TKI rechallenge and possibly preferring alternative strategies, such as immune checkpoint inhibitors, after PD to a treatment line including a TKI in this setting.